Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine

Highlights • Brimonidine is very highly selective toward the α2 -adrenergic receptors. • Brimonidine is more potent than oxymetazoline on subcutaneous small vessels (<200 μm). • Brimonidine has vasoconstrictive properties and reduces levels of skin edema. • Brimonidine could be beneficial in the...

Full description

Saved in:
Bibliographic Details
Published inJournal of dermatological science Vol. 75; no. 1; pp. 49 - 54
Main Authors Piwnica, David, Rosignoli, Carine, de Ménonville, Séverine Thibaut, Alvarez, Thierry, Schuppli Nollet, Marlene, Roye, Olivier, Jomard, André, Aubert, Jérôme
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ireland Ltd 01.07.2014
Subjects
Adrenergic alpha-2 Receptor Agonists - pharmacology
Animals
Anti-Inflammatory Agents - pharmacology
Biopsy
Brimonidine
Brimonidine Tartrate
Dermatology
Disease Models, Animal
Female
Humans
Inflammation
Inflammation - chemically induced
Inflammation - metabolism
Inflammation - prevention & control
Mice, Inbred BALB C
Mirvaso
Pharmacology
Quinoxalines - pharmacology
Receptors, Adrenergic, alpha-2 - drug effects
Receptors, Adrenergic, alpha-2 - metabolism
Rosacea
Skin - blood supply
Tissue Culture Techniques
Vascular
Vasoconstrictor Agents - pharmacology
Vasodilation - drug effects
Brimonidine
Inflammation
Pharmacology
Vascular
Mirvaso
Rosacea
Online AccessGet full text

Cover

More Information
Summary:Highlights • Brimonidine is very highly selective toward the α2 -adrenergic receptors. • Brimonidine is more potent than oxymetazoline on subcutaneous small vessels (<200 μm). • Brimonidine has vasoconstrictive properties and reduces levels of skin edema. • Brimonidine could be beneficial in the treatment of facial erythema in rosacea.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0923-1811
1873-569X
DOI:10.1016/j.jdermsci.2014.04.002